Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000506595 http://scihub22266oqcxt.onion/10.1159/000506595 32069472!7315220!32069472     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Princ+Pract 2020 ; 29 (3): 292-298 Nephropedia Template TP {{tp|p=32069472|t=2020. Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma |pdf=|usr=}}{{32069472}} gab.com Text Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma JO: Med Princ Pract http://www.kidney.de/pget.php?&tw=1&pmid=32069472 #FOAvip OBJECTIVE: Systemic administration of magnesium sulfate (MgSO4) has been proposed as a treatment for pediatric patients with acute asthma. However, previous trials show mixed results and uncertain evidence of benefit. The aim of the study was to ascertain whether intravenous (IV) MgSO4 improves lung function parameters in children with acute asthma. METHODS: This was a prospective clinical trial. All patients with acute asthma received 40-50 mg/kg or maximum 1,500 mg (>30 kg) of single dose IV MgSO4, administered over 60 min. Spirometry was conducted before and 15 min after MgSO4 infusion. RESULTS: One hundred and fifteen children aged 6 to 17 years presenting with acute asthma and FEV1 between 40% and 75% of predicted were included. Then, the patients were classified into 2 groups; mild asthma attack (FEV1 ranged from 60% to 75%; n = 50) or moderate asthma attack (FEV1 ranged from 40% to 59%; n = 65). The baseline characteristics were similar in both groups. The mean percent predicted pre and post values for FEV1/FVC ratio (mild group: 82.59 +/- 9.46 vs. 85.06 +/- 8.95; moderate group: 77.31 +/- 11.17 vs. 79.99 +/- 11.77), FEV1 (mild group: 67.14 +/- 4.99 vs. 72.29 +/- 8.05; moderate group: 48.50 +/- 6.81 vs. 53.78 +/- 9.81), PEF (mild group: 65.49 +/- 12.32 vs. 71.37 +/- 12.96; moderate group: 47.56 +/- 11.78 vs. 51.97 +/- 13.98), and FEF25-75 (mild group: 58.20 +/- 12.24 vs. 66.57 +/- 16.95; moderate group: 37.77 +/- 11.37 vs. 43.41 +/- 14.19) showed a statistically significant (p < 0.05 for all) bronchodilator effect after MgSO4 infusion in both groups with few side effects. CONCLUSION: Administration of IV MgSO4 was associated with improved pulmonary function in children with acute asthma. Twit Text FOAVip Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma ????Med Princ Pract http://www.kidney.de/pget.php?&tw=1&pmid=32069472 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32069472 #FOAvip English Wikipedia <ref>{{Cite pmid|32069472}}</ref> Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma #MMPMID32069472 Ozdemir A; Dogruel D Med Princ Pract 2020[]; 29 (3): 292-298 PMID32069472show ga OBJECTIVE: Systemic administration of magnesium sulfate (MgSO4) has been proposed as a treatment for pediatric patients with acute asthma. However, previous trials show mixed results and uncertain evidence of benefit. The aim of the study was to ascertain whether intravenous (IV) MgSO4 improves lung function parameters in children with acute asthma. METHODS: This was a prospective clinical trial. All patients with acute asthma received 40-50 mg/kg or maximum 1,500 mg (>30 kg) of single dose IV MgSO4, administered over 60 min. Spirometry was conducted before and 15 min after MgSO4 infusion. RESULTS: One hundred and fifteen children aged 6 to 17 years presenting with acute asthma and FEV1 between 40% and 75% of predicted were included. Then, the patients were classified into 2 groups; mild asthma attack (FEV1 ranged from 60% to 75%; n = 50) or moderate asthma attack (FEV1 ranged from 40% to 59%; n = 65). The baseline characteristics were similar in both groups. The mean percent predicted pre and post values for FEV1/FVC ratio (mild group: 82.59 +/- 9.46 vs. 85.06 +/- 8.95; moderate group: 77.31 +/- 11.17 vs. 79.99 +/- 11.77), FEV1 (mild group: 67.14 +/- 4.99 vs. 72.29 +/- 8.05; moderate group: 48.50 +/- 6.81 vs. 53.78 +/- 9.81), PEF (mild group: 65.49 +/- 12.32 vs. 71.37 +/- 12.96; moderate group: 47.56 +/- 11.78 vs. 51.97 +/- 13.98), and FEF25-75 (mild group: 58.20 +/- 12.24 vs. 66.57 +/- 16.95; moderate group: 37.77 +/- 11.37 vs. 43.41 +/- 14.19) showed a statistically significant (p < 0.05 for all) bronchodilator effect after MgSO4 infusion in both groups with few side effects. CONCLUSION: Administration of IV MgSO4 was associated with improved pulmonary function in children with acute asthma. |Acute Disease[MESH] |Administration, Intravenous[MESH] |Adolescent[MESH] |Anti-Asthmatic Agents/administration & dosage/*therapeutic use[MESH] |Asthma/*drug therapy[MESH] |Child[MESH] |Dose-Response Relationship, Drug[MESH] |Female[MESH] |Hospitals, Pediatric[MESH] |Humans[MESH] |Magnesium Sulfate/administration & dosage/*therapeutic use[MESH] |Male[MESH] |Prospective Studies[MESH] |Respiratory Function Tests[MESH]Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma (epmc).pdf DeepDyve Pubget Overpricing